<code id='75D4EB9730'></code><style id='75D4EB9730'></style>
    • <acronym id='75D4EB9730'></acronym>
      <center id='75D4EB9730'><center id='75D4EB9730'><tfoot id='75D4EB9730'></tfoot></center><abbr id='75D4EB9730'><dir id='75D4EB9730'><tfoot id='75D4EB9730'></tfoot><noframes id='75D4EB9730'>

    • <optgroup id='75D4EB9730'><strike id='75D4EB9730'><sup id='75D4EB9730'></sup></strike><code id='75D4EB9730'></code></optgroup>
        1. <b id='75D4EB9730'><label id='75D4EB9730'><select id='75D4EB9730'><dt id='75D4EB9730'><span id='75D4EB9730'></span></dt></select></label></b><u id='75D4EB9730'></u>
          <i id='75D4EB9730'><strike id='75D4EB9730'><tt id='75D4EB9730'><pre id='75D4EB9730'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:161
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          NYU radiologists take on the challenge of expensive MRI machines
          NYU radiologists take on the challenge of expensive MRI machines

          ResearchersatNYUduringahackathontobuildanMRIfromscratch.CourtesyNYUHowmanyscientistsdoesittaketobuil

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          In key trial, Verve's treatment lowers cholesterol levels in patients

          APStockVerveTherapeuticssaidSundaythatthefirst10peopletoreceiveaone-timetreatmentpoweredbyaformofCRI